NewLink nosedives on IMPRESS news

NewLink Genetics Corp. (NASDAQ:NLNK) lost $15.59 (30%) to $36.55 on Tuesday following Monday's post-market news that it would continue the Phase III IMPRESS trial of HyperAcute Pancreas algenpantucel-L to treat resected pancreatic cancer.

NewLink based its decision on a second interim analysis. It previously had said the ideal outcome would have been interim data showing an improvement in overall survival that would support a regulatory submission. ...